Answers are grounded in this paper and cite their sources.
In November 2019, Karolinska hospital announced plans to cut some 600 medical posts (350 nurses and 250 physicians), in addition to already laying off 550 administrative staff earlier last year, all in an attempt to plug a hole of SEK1.6bn (£128 m; €150 m; $165 m) in the hospital's budget for 2019.1 In Italy, 18 out of 20 regions spent more on healthcare than was budgeted in 2016, while in the UK, NHS' drugs bills were 33.7% higher in 2017 compared to 2010, with an average annual growth rate of 4.1% in the past 3 years.2, 3 In the era of precision medicines with a promise of optimized drug efficacy and safety, where therapies are administered according to the patient's and/or disease's genomic profiles, it should come as no surprise that monoclonal antibodies and other biological molecules are being approved at twice the rate of small therapeutic molecules while also commanding exorbitant market prices.4 This has been the case particularly in the field of oncology, where targeted biologicals have offered increased chances for survival to a proportion of patients at a high cost. Another example of increased expenditure is the case of orphan drugs, where a very low number of patient demands makes it financially unappealing for the pharmaceutical industry to develop drugs for orphan indications. With that in mind, specific regulations were put in place in the USA and the EU, which worked better than expected, and produced at least 73 orphan drug indications in the EU since 2000, and 335 indications in the USA since 2002.5 Without a price ceiling or maximum budget impact imposed on the orphan drugs' marketing authorisation holders, such medicines are usually very expensive and typically labelled as not cost-effective by the health technology assessment agencies.6 Moreover, pharmaceutical companies have used existing orphan drug regulations to split indications into groups that are small enough so that their already registered drugs could also qualify for an orphan drug label in additional indications.7 The current trends of increasingly rising drug prices worldwide have been brought forth by patent established monopolies, unanticipated consequences of drug registration and reimbursement policies as well as market failure.5 The result of these processes is that modern healthcare gradually becomes unaffordable, even for developed countries, as increases in drug costs percentwise outpace the rise in national gross domestic products. There is a range of mechanisms and policy tools that can be used to control drug prices. One approach is to involve drug prescribers in price control programmes, by either rewarding doctors when their prescription expenses are low or introducing penalization in cases when they exceed expense limits. Another way of controlling drug prices is to have physicians prescribe only by use of the International Nonproprietary Names of drugs and use the brand names only when this is truly required.8 The pharmacists are then left to dispense the drug according to the International Nonproprietary Name. Of all drug price control measures, reference pricing has been proven most effective in reducing drug pricing and it can be performed either internally, when drugs with the same active compound or equal clinical effects are compared on a national level, or externally (internationally), which is used by most EU countries, where drug prices are compared between countries with the same economic power or adjusted for purchasing power parity in instances where this is not the case.9 The drawbacks of this approach are that it does not take into account undisclosed discounts applied to drug prices published on the payers' official lists while it also encourages marketing authorisation holders to prioritize countries with the highest purchasing power for drug registration, thus limiting or delaying drug availability in lower and middle income countries.10 Biosimilar interchangeability and substitution are additional expenditure control measures. Although biosimilar compounds have significantly higher development costs in comparison to small molecule generics, the savings accrued can be significant.11 The European Medicines Agency's decision to assign biosimilar substitution policies to EU member state national authorities has led to an uneven approach to biosimilar and originator drug interchangeability between different European countries as well as uncertainty among some physicians and patients regarding biosimilar safety and efficacy. Nevertheless, increased involvement of professional medical community in biosimilar prescribing guidelines might improve cost control policies significantly.12 Open tendering and price or profit ceilings are alternative methods of healthcare cost control. Countries using open tendering invite drug companies and wholesalers to propose confidential prices for which they can guarantee to be capable of supplying specific drugs usually for a period of 2 years. Bidders offering the lowest price are awarded a contract with a secured income for the agreed time period. An important downside of open tendering appears in a situation where the winning supplier fails to deliver the drug, thus forcing a purchase of drug supply elsewhere, invariably under open market conditions.13 Additionally, for companies that have failed to secure a contract in an open tender process, it can be difficult to participate in subsequent tendering rounds, due to loss of manufacturing capacity and competitiveness, which can help create new monopolies leading to paradoxically increased prices.14 A good example of a profit ceiling aimed at control of medicine price hikes is the Pharmaceutical Price Regulation Scheme in the UK, under which a company has to reduce its drug price, postpone price increases or pay back the excess profit to the Department of Health, in cases where its profits exceed the amount agreed on during negotiations.9 Different countries can also join together for the purposes of transnational licensing and pricing frameworks and thus increase their bargaining power, such as Belgium, the Netherlands and several other European countries have done by forming a bloc with an aim to negotiate lower prices for orphan drugs.15 Furthermore, such blocs of countries could potentially present an opportunity for not for profit organisations to develop and market more affordable orphan drugs since 1 in 5 orphan drugs is already repurposed.6 Last but not least, value-based pricing is used in many countries today as a factor in the reimbursement decision making process. The British regulator set the threshold for cost effectiveness at 30 000 GBP per quality adjusted life year (QALY) and at 50 000 GBP for end of life drugs.16 In other European countries, QALY thresholds are set between 10 000 EUR and 80 000 EUR per QALY. Since cost effectiveness thresholds are different across European countries, this also explains the differences in the drug prices. Moreover, due to a lack of standardisation, many therapies that are not deemed cost effective still end up being reimbursed, often by specific funds, such as the English Cancer Drug Fund. In conclusion, the pharmaceutical industry is setting high drug prices for the new biological molecules that are in line with the cost effectiveness thresholds that a particular country is willing to pay; however, these prices often do not reflect the drugs' true value and even the developed countries could find such increased expenditure for novel therapies hardly affordable in the long run. To preserve equitable access to medicines as well as a balance between rewarding pharmaceutical industry's innovation and governments' drug reimbursements, a number of policy measures can be employed, ranging from biosimilar substitution, generic prescribing and price referencing to engaging physicians and pharmacists in prescribing cost control, open tendering and transnational price negotiations. The most promising long-term measures seem to be outcome based and pay-for-performance pricing policies, which would allow for ongoing renegotiation of drug prices based on their real-life performance and treatment outcomes as well as sale volumes. Clinical pharmacologists have the necessary skills and expertise and are uniquely professionally positioned to have a pivotal role in this process. There are no competing interests to declare.
No takes yet. Share an insight, caveat, or question.
Robert Likić (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: